問卷

TPIDB > Search Result

Search Result

篩選

List

179Cases

2025-10-01 - 2028-12-31

Active
A phase 2b, randomized, double-blind, placebo-controlled, parallel, multiple-dose trial was conducted to evaluate the efficacy, safety, and pharmacokinetics of AZD0292 in patients aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa grafts.
  • Condition/Disease

    In NCFBE and chronic PsA transfer subjects, the effect of AZD0292 IV every 4 weeks (Q4W) compared with placebo on the incidence of moderate to severe acute lung exacerbations was evaluated.

  • Test Drug

    AZD0292

Participate Sites
7Sites

Recruiting7Sites

2025-10-31 - 2029-06-26

Not yet recruiting
A phase 2b, randomized, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of Verekitug (UPB-101) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).
  • Condition/Disease

    Moderate to severe chronic obstructive pulmonary disease (COPD)

  • Test Drug

    UPB-101

Participate Sites
8Sites

Not yet recruiting8Sites

2024-06-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2005-07-01 - 2008-07-01

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2023-03-01 - 2027-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2020-02-01 - 2025-12-10

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

2007-11-14 - 2009-12-29

Phase II/III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2007-10-01 - 2008-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2021-01-01 - 2026-06-30

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2020-02-05 - 2021-12-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites